MEN1 and cancer: Targeting/silencing miR-24, during the hyperplastic phase of parathyroid and endocrine pancreas tumorigenesis and before the occurrence of the somatic MEN1 LOH, could by a promising tissue-specific RNA-based anti-cancer therapy, aimed to restore the correct expression of menin in pre-cancerous cells.